Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.

Jungk C, Mock A, Exner J, Geisenberger C, Warta R, Capper D, Abdollahi A, Friauf S, Lahrmann B, Grabe N, Beckhove P, von Deimling A, Unterberg A, Herold-Mende C.

BMC Med. 2016 Oct 26;14(1):170.

2.

Rapid Reprogramming of Primary Human Astrocytes into Potent Tumor-Initiating Cells with Defined Genetic Factors.

Li F, Liu X, Sampson JH, Bigner DD, Li CY.

Cancer Res. 2016 Sep 1;76(17):5143-50. doi: 10.1158/0008-5472.CAN-16-0171.

PMID:
27364552
3.

Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery.

Chen F, Becker A, LoTurco J.

Curr Protoc Pharmacol. 2016 Mar 18;72:14.37.1-12. doi: 10.1002/0471141755.ph1437s72. Review.

4.

Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma.

Fujikawa A, Nagahira A, Sugawara H, Ishii K, Imajo S, Matsumoto M, Kuboyama K, Suzuki R, Tanga N, Noda M, Uchiyama S, Tomoo T, Ogata A, Masumura M, Noda M.

Sci Rep. 2016 Feb 9;6:20473. doi: 10.1038/srep20473.

5.

Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models.

Irvin DM, McNeill RS, Bash RE, Miller CR.

Brain Pathol. 2017 Jan;27(1):36-50. doi: 10.1111/bpa.12348.

PMID:
26762242
6.

Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials.

Le Tourneau C, Kamal M, Tsimberidou AM, Bedard P, Pierron G, Callens C, Rouleau E, Vincent-Salomon A, Servant N, Alt M, Rouzier R, Paoletti X, Delattre O, Bi├Ęche I.

J Natl Cancer Inst. 2015 Nov 23;108(4). pii: djv362. doi: 10.1093/jnci/djv362. Review.

7.

Adult Lineage-Restricted CNS Progenitors Specify Distinct Glioblastoma Subtypes.

Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa KJ, Raisanen JM, Burns DK, Johnson JE, Parada LF.

Cancer Cell. 2015 Oct 12;28(4):429-40. doi: 10.1016/j.ccell.2015.09.007.

8.

Tracking and transforming neocortical progenitors by CRISPR/Cas9 gene targeting and piggyBac transposase lineage labeling.

Chen F, Rosiene J, Che A, Becker A, LoTurco J.

Development. 2015 Oct 15;142(20):3601-11. doi: 10.1242/dev.118836.

9.

Modeling cytomegalovirus infection in mouse tumor models.

Price RL, Chiocca EA.

Front Oncol. 2015 Mar 17;5:61. doi: 10.3389/fonc.2015.00061.

10.

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

El Meskini R, Iacovelli AJ, Kulaga A, Gumprecht M, Martin PL, Baran M, Householder DB, Van Dyke T, Weaver Ohler Z.

Dis Model Mech. 2015 Jan;8(1):45-56. doi: 10.1242/dmm.018168.

11.

The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models.

Carnero A, Paramio JM.

Front Oncol. 2014 Sep 23;4:252. doi: 10.3389/fonc.2014.00252. Review.

12.

The impact of coexisting genetic mutations on murine optic glioma biology.

Kaul A, Toonen JA, Gianino SM, Gutmann DH.

Neuro Oncol. 2015 May;17(5):670-7. doi: 10.1093/neuonc/nou287.

13.

Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma.

Ozawa T, Riester M, Cheng YK, Huse JT, Squatrito M, Helmy K, Charles N, Michor F, Holland EC.

Cancer Cell. 2014 Aug 11;26(2):288-300. doi: 10.1016/j.ccr.2014.06.005.

14.

Nitroxoline induces apoptosis and slows glioma growth in vivo.

Lazovic J, Guo L, Nakashima J, Mirsadraei L, Yong W, Kim HJ, Ellingson B, Wu H, Pope WB.

Neuro Oncol. 2015 Jan;17(1):53-62. doi: 10.1093/neuonc/nou139.

15.

In vivo models of brain tumors: roles of genetically engineered mouse models in understanding tumor biology and use in preclinical studies.

Simeonova I, Huillard E.

Cell Mol Life Sci. 2014 Oct;71(20):4007-26. doi: 10.1007/s00018-014-1675-3. Review.

16.

Glial progenitors as targets for transformation in glioma.

Ilkanizadeh S, Lau J, Huang M, Foster DJ, Wong R, Frantz A, Wang S, Weiss WA, Persson AI.

Adv Cancer Res. 2014;121:1-65. doi: 10.1016/B978-0-12-800249-0.00001-9. Review.

17.

Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells.

Kim TH, Song J, Kim SH, Parikh AK, Mo X, Palanichamy K, Kaur B, Yu J, Yoon SO, Nakano I, Kwon CH.

Neuro Oncol. 2014 Oct;16(10):1354-64. doi: 10.1093/neuonc/nou088.

18.

PTEN degradation after ischemic stroke: a double-edged sword.

Li W, Huang R, Chen Z, Yan LJ, Simpkins JW, Yang SH.

Neuroscience. 2014 Aug 22;274:153-61. doi: 10.1016/j.neuroscience.2014.05.027.

19.

In vivo optical imaging of brain tumors and arthritis using fluorescent SapC-DOPS nanovesicles.

Chu Z, LaSance K, Blanco V, Kwon CH, Kaur B, Frederick M, Thornton S, Lemen L, Qi X.

J Vis Exp. 2014 May 2;(87). doi: 10.3791/51187.

20.

Brain stem cells as the cell of origin in glioma.

Modrek AS, Bayin NS, Placantonakis DG.

World J Stem Cells. 2014 Jan 26;6(1):43-52. doi: 10.4252/wjsc.v6.i1.43. Review.

Supplemental Content

Support Center